You are here

Novartis’s Orphan Drug Ilaris May Help Heart Attack Survivors, Study Shows

But the $16,000 price tag is a problem

A recent clinical trial showed that a drug used for a small coterie of patients suffering from rare inflammatory disorders can reduce the risks of serious complications in people who have suffered a heart attack.

The drug, called ACZ885 (brand name Ilaris), is manufactured by Novartis, which now faces a dilemma, reports the Wall Street Journal. It costs $16,000 per dose. “If the drug does pan out with regulators, Novartis would have to drastically cut its price to make it competitive with other cardiovascular drugs,” the newspaper reports. “That would mean jettisoning a small, but reliable, revenue stream on an uncertain bet that the drug could become a top seller as a cardiovascular medicine.”

It’s a pickle, as Novartis knows. A company spokesperson tells the WSJ: “We will continue to fully analyze the data, plan to discuss these with regulatory agencies, and determine how it would fit into clinical practice.”

Novartis made about $288 million last year selling Ilaris. It could possibly make $3.6 billion selling to heart attack patients, even if it greatly reduced the price. “If approved for use in patients recovering from a heart attack, ACZ885’s potential market would skyrocket: around 615,000 people in the U.S. survive a heart attack every year, according to the American Heart Association,” the WSJ reports. “Novartis estimates that the drug, which helps patients who also suffer from inflammation in the arteries, could be suitable in around 40% of those cases.”

Source: Wall Street Journal; July 12, 2017.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs